Methods	Allocation: random, no further details. Blindness: double, no further details. Duration: 16 weeks (first 8 weeks observed). Design: cross-over. Location: not reported. Country: not reported.
Participants	Diagnosis: schizophrenia. N=8. Age: not reported. Sex: not reported. History: duration ill not reported, age at onset not reported. Setting: in- and outpatient.
Interventions	Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported
Outcomes	Global State: CGI. Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore depression Calgary depression scale Unable to use - Global state: CGI (no usable data). Mental State: (no usable data).
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Random, no further details.
Allocation concealment?	Unclear risk	No further details.
Blinding? Objective outcomes	Low risk	Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Blinding? Subjective outcomes	Unclear risk	Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding
Incomplete outcome data addressed? All outcomes	High risk	Data on leaving the study early were not available.
Free of selective reporting?	High risk	Data were only presented as a poster, data on primary outcomes were missing
Free of other bias?	High risk	The study was sponsored by the manufacturers of olanzapine.